Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Inclusion Criteria: * Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix * Biopsy result positive for carcinoma within 60 days prior to registration * FIGO clinical stage I-IVA disease, based on standard diagnostic workup, including:History/physical examination and/or Examination under anesthesia (if indicated) * If the patient is status post hysterectomy, one or more of the following conditions must be present: positive lymph nodes, positive margins, parametrial invasion, or non-radical surgery (i.e., simple hysterectomy). * If the patient is inoperable, one or more of the following conditions must be present: clinical stage IB2-IVA, positive lymph nodes on nodal sampling or frozen section, and/or parametrial invasion * Within 42 days prior to registration, the patient must have any of the following, if clinically indicated: examination under anesthesia, cystoscopy, sigmoidoscopy, rigid proctoscopy, or colonoscopy. * X-ray (PA and lateral), CT scan, or PET/CT scan of the chest within 42 days prior to registration; * CT scan, MRI, or PET/CT of the pelvis within 42 days prior to registration; * Karnofsky Performance Status 60-100 * Absolute neutrophil count (ANC) ≥ 1500 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10.0 g/dl is acceptable); Creatinine clearance ≥ 50 mg/dl; Bilirubin \< 1.5 mg/dl; WBC ≥ 3,000/μl; ALT/AST \< 3 x ULN; INR ≤ 1.5 * Negative serum pregnancy test for women of child-bearing potential Exclusion Criteria: * Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years; * Prior systemic chemotherapy within the past three years * Prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields; * Para-aortic, inguinal, or gross (unresected) pelvic nodal metastasis. Gross pelvic nodal metastasis is defined as either: Radiographic evidence of nodal metastasis on CT or MRI (node having short axis diameter \> 1 cm)OR Radiographic evidence of nodal metastasis on diagnostic FDG-PET or PET/CT scan (abnormally increased FDG uptake as determined and documented by the radiologist)OR Biopsy-proven metastasis (e.g. needle biopsy) in undissected node * Distant metastasis * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects * Uncontrolled diabetes, defined as diabetes mellitus, which in the opinion of any of the patient's physicians requires an immediate change in management; * Uncompensated heart disease or uncontrolled high blood pressure * Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition